又一家 AI 明星公司诞生:曝“医生版 ChatGPT”OpenEvidence 估值冲上 150 亿美元Another AI Star is Born: Reports Say "Doctor's ChatGPT" OpenEvidence Valuation Surges to $15 Billion


AI free token/AI免费积分

IT之家 9 月 25 日消息,据《商业内幕》今天(25 日)报道,面向医生给出 AI 搜索服务的 OpenEvidence,成为又一家在短期内连续完成两轮融资的 AI 明星公司。

知情人士称,OpenEvidence 近期取得多家医院平台和安德森 · 霍洛维茨合计 2.5 亿美元(IT之家注:现汇率约合 16.79 亿元人民币)投资,估值升至 150 亿美元(现汇率约合 1,007.59 亿元人民币)。今年 1 月,OpenEvidence 刚完成一轮融资,当时估值为 120 亿美元(现汇率约合 806.07 亿元人民币)。

又一家 AI 明星公司诞生:曝“医生版 ChatGPT”OpenEvidence 估值冲上 150 亿美元

一名知情人士称,OpenEvidence 或愿意考虑出售公司,其中还涵盖算力资源的使用权。如果反 AI 情绪持续升温并阻碍数据中心扩建,将来算力供应可能趋于紧张。当下尚无法核实是否已有潜在收购方对 OpenEvidence 表达并购兴趣,公司也可能挑选继续保持独立。

OpenEvidence 总部设在迈阿密,过去一年融资总额超过 10 亿美元(现汇率约合 67.17 亿元人民币),投资者涵盖 Thrive Capital、DST、GV、凯鹏华盈和红杉资本。OpenEvidence 将旗下 AI 搜索引擎称为“史上增长最快的医生应用”。

OpenEvidence 完成新一轮融资之际,OpenAI、Anthropic 等 AI 巨头正进一步拓展医疗业务。除了向其他公司的机型给出底层模型,这些 AI 巨头也越来越多地亲自开发医疗工具。

对于潜在收购方,OpenEvidence 可以省去从零进入医疗市面的过程。OpenEvidence 已积累了医生使用者,也具备处理敏感医疗信息的经验,并在 AI 公司越来越希望占据的庞大市面中取得立足点。

OpenEvidence 创立于 2022 年,机型已在医疗专业人士中得到广泛使用,美国超过三分之二的医生依靠其获取诊断和治疗建议。

OpenEvidence 与多家大型科技公司保持业务关系,英伟达也是投资者之一。该公司不仅在本周与 Anthropic 达成合作,先前还接入了谷歌和微软的 AI 工具。

本文来源:https://www.ithome.com/1/007/161.htm
若有版权问题,请来信告知:13951431913#139.com 或在右方提交评论。

ITHome, Sept 25 news: According to Business Insider today (Sept 25), OpenEvidence, which offers AI search services to doctors, has become another AI star company to complete two funding rounds in a short period.

According to people familiar with the matter, OpenEvidence recently secured a combined $250 million investment (ITHome note: approx. 1.679 billion RMB at current exchange rate) from multiple hospital platforms and Andreessen Horowitz, with its valuation rising to $15 billion (approx. 100.759 billion RMB at current exchange rate). In January this year, OpenEvidence had just completed a funding round at a valuation of $12 billion (approx. 80.607 billion RMB at current exchange rate).

Another AI Star is Born: Reports Say

One person familiar with the matter stated that OpenEvidence may be willing to consider selling the company, including the rights to use its computing resources. If anti-AI sentiment continues to rise and obstructs data center expansion, future computing supply may become tight. It is currently not possible to verify whether any potential acquirer has expressed interest in M&A for OpenEvidence, and the company may also choose to remain independent.

OpenEvidence is headquartered in Miami and has raised over $1 billion (approx. 6.717 billion RMB at current exchange rate) in total funding over the past year, with investors including Thrive Capital, DST, GV, Sequoia Capital, and KAI-PE. OpenEvidence calls its AI search engine "the fastest-growing doctor application in history."

As OpenEvidence completes its new round of financing, AI giants such as OpenAI and Anthropic are further expanding their medical business. In addition to providing foundational models to other companies' models, these AI giants are increasingly developing medical tools themselves.

For potential acquirers, OpenEvidence can save the process of entering the medical market from scratch. OpenEvidence has already accumulated a user base of doctors, possesses experience in handling sensitive medical information, and has secured a foothold in the vast market where AI companies increasingly seek a presence.

OpenEvidence was founded in 2022, and its model has been widely used among medical professionals; more than two-thirds of doctors in the United States rely on it to obtain diagnostic and treatment advice.

OpenEvidence maintains business relationships with several major tech companies, with Nvidia also being one of its investors. The company not only reached a partnership with Anthropic this week but also previously integrated AI tools from Google and Microsoft.

暂无评论,快来发表第一条评论吧!No comments yet. Be the first!

📮 需求咨询📮 Inquiry